Particle Sciences and Microfluidics Collaborate to Share Formulation and Nanotechnology Expertise for Pharmaceutical Drug Product Development, Analysis and Commerc...(orldwide. Combining 25 years of proven p...)

Date:6/30/2009

orldwide. Combining 25 years of proven processing success with PSI's experience creates a uniquely comprehensive solution portfolio for the Company's pharmaceutical clients. In addition, Microfluidics Reaction Technology (MRT), an innovative technique for bottom-up nanoparticle creation and nanoencapsulation via continuous crystallization and chemical reactions, offers even more possibilities in novel drug development and will also be incorporated into PSI's offerings.

As part of the non-exclusive agreement, Particle Sciences has installed an M-110EH-30 Basic BioPharma Microfluidizer processor ideal for nanoemulsions, nanosuspensions, cell disruption and nanoencapsulation in pilot and production volumes.

"We believe Microfluidizer processors are the undisputed gold standard in the pharmaceutical industry, from the lab to clinical research and production," said Bill Kober, Vice President of Sales, Americas, at Microfluidics. "With several well-known drugs on the market, customers use our processors to reduce particle sizes uniformly, improve bioavailability and target drug delivery. Through this relationship, our users now have access to our technology combined with the scientific ingenuity and experience of Particle Sciences. We are excited to provide a uniquely complete portfolio of solutions for global API research and development."

About Microfluidics

Microfluidics, a wholly owned subsidiary of Microfluidics International Corporation, is a supplier of advanced fluid processing equipment and reaction technology for laboratory, pilot scale and manufacturing applications. The equipment enables the formulation and manufacture of numerous nanomaterials and nanoscale products and produces the most uniform and smallest liquid and suspended solid particles available. Microfluidics has been a worldwide supplier of Microfluidizer(R) high shear fluid processing systems to the biotechnology,
'/>"/>

SOURCE Particle Sciences Inc. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related biology technology :

1. Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
2. Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
3. Hector Garcia Joins Particle Sciences as Director of Quality Assurance
4. Xspray Expands to Meet Pharmas Interest in its Ground-Breaking Particle Production Technology
5. Fat droplet nanoparticle delivers tumor suppressor gene to tumor and metastatic cells
6. NOVAVAX Announces Publication of a Preclinical Study Demonstrating that a Virus-like Particle Vaccine Provided Protection Against Highly Pathogenic H1N1 and H5N1 Influenza Strains
7. Paper electrified by copper particles
8. Particle Sciences Completes Development of First Product Incorporating its Unique Surface Modification System
9. Safer nanoparticles spotlight tumors, deliver drugs
10. Gold-palladium nanoparticles achieve greener, smarter production of hydrogen peroxide
11. Nanoparticles double their chances of getting into sticky situations